EG 427 completes Series A financingOctober 30, 2022
EG 427, a biotechnology company developing pinpoint gene therapy, today announced the closing of a €12 million Series A round. The round was led by David Lamond in association with San Francisco based large family offices. The financing will be used to move the company’s leading vector construct forward to clinical trials in neurogenic bladder.
EG 427 focuses on creating a step-change in the gene therapy field by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and in particular its ability to establish lifelong latency in peripheral neurons. The company’s HSV-1-based vectors ensure highly specific and durable expression of transgenes to treat patients with severe, chronic, and localized diseases, starting with peripheral nervous system disorders.
Download the full press release / Télécharger le communiqué de presse intégral
See the story in the Wall Street Journal
See the story in "Los Echos" (in French)